article SEL120: a promising CDK8 kinase inhibitor 28 October 2019 | By Victoria Rees (Drug Target Review) A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.